Johnson & Johnson (JNJ) is in talks to buy Protagonist Therapeutics (PTGX), which had a market value of over $4B as of Thursday’s close, The Wall Street Journal’s Lauren Thomas and Ben Dummett report. J&J, which is already working with Protagonist to develop an oral treatment for immune diseases including plaque psoriasis and ulcerative colitis and has the exclusive rights to commercialize the product, already owns nearly 4% of Protagonist’s shares, according to FactSet.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump Trade: GoodRx, others in talks with White House to join TrumpRx
- Johnson & Johnson price target raised to $209 from $185 at RBC Capital
- Johnson & Johnson price target raised to $178 from $176 at Morgan Stanley
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports
- Trump Trade: Generics to be excluded from pharma tariff plan